Bayer Secures Breakthrough Status for Sevabertinib in HER2 NSCLC
US FDA and China’s CDE granted the designation for sevabertinib as a potential first-line therapy in advanced HER2-mutant non-small cell lung cancer.
The US Food And Drug Administration | 07/01/2026 | By News Bureau | 117
US FDA Grants Six More Priority Review Vouchers to Accelerate Drug Approvals
The US Food and Drug Administration (FDA) has awarded six additional companies under its “Commissioner’s National Priority Voucher” programme, bringing the total number of recipients to fifteen.
The US Food And Drug Administration | 07/11/2025 | By Darshana | 153
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy